Welcome to our dedicated page for Merit Med Sys SEC filings (Ticker: MMSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merit Medical Systems Inc. filings document operating and financial results, Regulation FD disclosures and material events for a medical-device manufacturer serving interventional, diagnostic and therapeutic markets. Recent Form 8-K reports cover quarterly and annual results, conference-call materials, historical revenue information under the Foundational and Therapeutic product categories, and product-related updates.
The company’s proxy materials describe board composition, governance practices, executive compensation and shareholder voting matters. Other filed event reports address board-leadership changes, completed product-technology acquisitions, capital-structure disclosure categories and clinical or regulatory disclosures tied to Merit’s device portfolio.
Millner F. Ann Ed.D. reported acquisition or exercise transactions in this Form 4 filing.
MERIT MEDICAL SYSTEMS INC director receives equity award. Director F. Ann Millner was granted 3,457 restricted stock units under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan. These RSUs will vest on May 3, 2027, subject to her continued service with the company until that date.
Following this award, her reported direct holdings total 38,000 shares of common stock. This is a compensation-related grant rather than an open-market stock purchase or sale.
Merit Medical Systems, Inc. reported results from its 2026 annual meeting and related governance actions. Shareholders approved the 2026 Equity Incentive Plan, which authorizes awards such as stock options, restricted stock, and restricted stock units, and the 2026 Employee Stock Purchase Plan, allowing eligible employees to buy common stock through payroll deductions at a discount.
Shareholders elected Martha G. Aronson, Lonny J. Carpenter and Scott R. Ward to three-year board terms and Lynne N. Ward to a one-year term, and gave majority support to the advisory say-on-pay vote. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026. Following plan approval, the board adopted a base form restricted stock unit award agreement for directors and approved Fifth Amended and Restated Bylaws, which fully replace the prior bylaws.
MERIT MEDICAL SYSTEMS INC director Scott R. Ward has filed a Form 3, which is an initial statement of beneficial ownership. The data provided shows no reported transactions and no listed derivative positions, establishing his baseline disclosure as a reporting person for the company.
MERIT MEDICAL SYSTEMS INC Chief Commercial Officer Christian Adam Smith reported an open-market purchase of 1,626 shares of Common Stock at $61.00 per share on May 11, 2026 through a 401(k) plan. Following this transaction, his indirect 401(k) holdings total 2,220 shares of Common Stock.
Separately, he holds 30,334 shares of Common Stock directly. He also holds non-qualified stock options to acquire 25,000 shares of Common Stock at an exercise price of $70.50 per share, expiring on October 4, 2028, and options to acquire 8,259 shares at an exercise price of $73.95 per share, expiring on March 31, 2030.
Merit Medical Systems director Lynne N. Ward reported an open-market sale of 5,000 shares of common stock on 2026-05-07. The weighted average sale price was $62.607 per share, from trades between $62.395 and $62.815. Ward now directly holds 7,809 shares.
Merit Medical Systems’ chief legal officer Brian G. Lloyd reported an insider purchase of company stock. On May 7, 2026, an entity described as a 401(k) plan bought 2,000 shares of common stock at $62.625 per share, recorded as indirect ownership.
Following this transaction, Lloyd’s filing shows 62,132 shares of common stock held directly, plus the 2,000 shares held through the 401(k) plan. He also retains several blocks of non-qualified stock options to buy common shares, with exercise prices ranging from $37.71 to $70.58 and expirations between 2027 and 2030.
Merit Medical Systems President and CEO Martha Goldberg Aronson bought 2,000 shares of the company’s common stock in an open-market purchase at $60.44 per share. After this transaction, she directly owns 49,792 shares, indicating a modest increase in her personal stake.
MMSI submitted a Form 144 notice to offer 5,000 Common shares for sale, listed with a 05/07/2026 date. The filing lists two restricted stock lots of 2,914 shares dated 06/17/2022 and 2,086 shares dated 05/18/2024.
MERIT MEDICAL SYSTEMS INC Chief Financial Officer and Treasurer Raul Parra Jr. reported an open-market purchase of 1,500 shares of common stock at $61.01 per share on May 6, 2026. After this transaction, he directly holds 58,843 shares of common stock.
He also has an indirect interest in 2,699 shares held through a 401(k) Plan, representing plan holdings as of May 5, 2026. In addition, he holds non-qualified stock options for 13,576 underlying shares at an exercise price of $70.58 expiring on February 28, 2030, and options for 9,070 underlying shares at $65.03 expiring on February 28, 2029.
MERIT MEDICAL SYSTEMS INC executive Michel J. Voigt, the Chief Human Resources Officer, reported an open-market purchase of company stock through a retirement plan. He bought 2,250 shares of common stock at $60.65 per share, held indirectly via a 401(k) Plan, bringing those plan holdings to 2,265 shares as of the reported date.
Voigt also reports 46,127 shares of common stock held directly. In addition, he holds non-qualified stock options covering 11,076 shares at $70.58, 4,046 shares at $65.03, and 2,420 shares at $56.25, which become exercisable in 25% annual installments and expire between 2028 and 2030.